Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Hernandez-Camba, A.
- Arranz, L.
- Vera, I
- Carpio, D.
- Calafat, M.
- Lucendo, A. J.
- Taxonera, C.
- Marin, S.
- Garcia, M. J.
- Marin, G. Suris
- Rodriguez, E. Sanchez
- Carbajo, A. Y.
- De Castro, M. L.
- Martin-Cardona, A.
- Rodriguez-Lago, I
- Busquets, D.
- Bertoletti, F.
- Ausin, M. Sierra
- Tardillo, C.
- Malaves, J. Huguet
- Bujanda, L.
- Castaño A
- Domènech E
- Ramos, L.
- GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)
Grupos
Abstract
BACKGROUND: Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. AIMS: Our primary objective was to evaluate the effectiveness and safety of MMF in IBD. METHODS: IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented. RESULTS: A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4-37.5). CONCLUSION: Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1590-8658, 1878-3562
- Tipo:
- Article
- Páginas:
- 635-641
- PubMed:
- 34862115
- Factor de Impacto:
- 0,979 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
DIGESTIVE AND LIVER DISEASE ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 4
Documentos
- No hay documentos
Filiaciones
Keywords
- Crohn's disease; Inflammatory bowel disease; Mycophenolate mofetil; Ulcerative colitis
Portal de investigación